Loading clinical trials...

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Evaluation of the Effects of Sequential Multiple-Dose Regimens of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

NCT01376076•Forest Laboratories

View on ClinicalTrials.gov

Summary

This study will evaluate the effects of sequential multiple dose regimens of cariprazine on cardiac repolarization in patients with schizophrenia.

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men or women, age 18 to 50, inclusive
•Symptoms of schizophrenia or schizoaffective disorder first appearing a minimum of 1 year before screening
•Negative pregnancy test
•Normal physical examination results, vital signs, and clinical lab test results

Exclusion Criteria

•Axis II disorder severe enough to interfere with the study
•Smoking more than 20 cigarettes a day
•History or presence of cardiovascular disorder
•Pregnant/breast-feeding and/or planning to become pregnant/breast-feed
•Imminent risk of injuring self or others or causing significant property damage

Locations (4)

Forest Investigative Site 001

Glendale, California, United States

Forest Investigative Site 004

Long Beach, California, United States

Forest Investigative Site 002

Willingboro, New Jersey, United States

Forest Investigative Site 003

Houston, Texas, United States

Key Dates

Start Date

June 1, 2011

Primary Completion Date

February 1, 2012

Completion Date

February 1, 2012

Last Updated

February 8, 2012

Enrollment

129

ACTUAL participants

Conditions

Schizophrenia

Interventions

Cariprazine

DRUG

Risperidone/Moxifloxacin

DRUG

Risperidone/Moxifloxacin

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 8, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia